🇪🇺 Mayzent in European Union

EMA authorised Mayzent on 13 January 2020

Marketing authorisation

EMA — authorised 13 January 2020

  • Application: EMEA/H/C/004712
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Mayzent
  • Indication: Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
  • Status: approved

Read official source →

Mayzent in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is Mayzent approved in European Union?

Yes. EMA authorised it on 13 January 2020.

Who is the marketing authorisation holder for Mayzent in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.